Doublet Immunotherapy Disappoints in Gastric Cancer Study

The findings, in which doublet immunotherapy added to standard FOLFOX chemotherapy did not improve progression-free survival, underscore the importance of PD-L1 expression in immunotherapy trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/doublet-immunotherapy-disappoints-gastric-cancer-study-2024a1000gpz?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?